NEW DRUG DEVELOPMENT
STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.
STRAGEN designs and conducts the full development programme, from pre-clinical to manufacturing scale-up, paving the way to global registration.
ALX-009 CYSTIC FIBROSIS
An innovative first-in-class orphan drug combination of two endogenous substances addressing a strong unmet medical need by targeting Multi-Drug Resistant bacterial infections not treatable by current antibiotic therapies.
For additional info, please, visit : www.alaxia-pharma.eu
A first-in-class non-opioid painkiller with a safe, non-addictive, and innovative mode of action. STR-324 is the synthetic equivalent of natural human peptides inhibiting the degradation of endogenous painkillers, showing efficacy on acute and prolonged pain without the common side effects of opioids (animal models).